ritanserin has been researched along with Disease Models, Animal in 28 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risperidone, 5-HT2A receptor antagonists, and D1 receptor antagonistic drugs prevented and reversed cocaine-induced hyperthermia." | 7.96 | Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. ( Makiguchi, A; Okada, T; Shioda, K; Suda, S, 2020) |
| "The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated." | 7.73 | Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats. ( Fathollahi, Y; Naghdi, N; Rezaei, M, 2006) |
| "Ritanserin is a potent long-acting 5-HT2 antagonist that acts centrally." | 6.39 | Ritanserin and alcohol abuse and dependence. ( Meert, TF, 1994) |
| " Currently, a full clinical development program of ritanserin in cocaine and alcohol abuse is ongoing." | 6.17 | Addiction and the potential for therapeutic drug development. ( Janssen, PA, 1994) |
| "The impeding effect of MDL 28,133A in coronary thrombosis and the lack of hemodynamic effects suggests that MDL 28,133A may be of benefit in treatment of hyperthrombotic conditions without having hemodynamic side effects." | 5.29 | Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs. ( Bruns, GC; Dage, RC; Hsieh, CP; Sakai, K, 1994) |
| "Risperidone, 5-HT2A receptor antagonists, and D1 receptor antagonistic drugs prevented and reversed cocaine-induced hyperthermia." | 3.96 | Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. ( Makiguchi, A; Okada, T; Shioda, K; Suda, S, 2020) |
| " Single doses of 5-HT2 antagonists, mianserin (5mg/kg) and ritanserin (1mg/kg), effectively ameliorated withdrawal anxiety in the rat, returning behavioural function in the social interaction test and elevated plus maze to levels comparable to vehicle-treated animals." | 3.73 | Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists. ( Begg, DP; Hallam, KT; Norman, TR, 2005) |
| "The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated." | 3.73 | Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats. ( Fathollahi, Y; Naghdi, N; Rezaei, M, 2006) |
| "The effect of inositol as an antidepressant was previously demonstrated in both animal models of depression-like behavior and in clinical trials." | 3.71 | The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. ( Belmaker, RH; Bourin, M; Clenet, F; Einat, H; Shaldubina, A, 2001) |
| "Ritanserin is a potent long-acting 5-HT2 antagonist that acts centrally." | 2.39 | Ritanserin and alcohol abuse and dependence. ( Meert, TF, 1994) |
| "Both paroxetine and pargyline were effective in reducing the immobility time of stressed OVX mice in the FST." | 1.38 | Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system. ( Bazanella Sampaio, T; Mozzaquatro Gai, B; Nogueira, CW; Pinton, S; Trevisan da Rocha, J; Zeni, G, 2012) |
| "Pretreatment with propranolol (10 mg/kg), a 5-HT(1A) receptor antagonist as well as a beta-blocker, and dantrolene (20 mg/kg), a peripheral muscle relaxant, did not prevent the death of the animals, even though these two drugs suppressed the increase in rectal temperature to some extent." | 1.31 | Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. ( Katoh, S; Nisijima, K; Yoshino, T; Yui, K, 2001) |
| "The impeding effect of MDL 28,133A in coronary thrombosis and the lack of hemodynamic effects suggests that MDL 28,133A may be of benefit in treatment of hyperthrombotic conditions without having hemodynamic side effects." | 1.29 | Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs. ( Bruns, GC; Dage, RC; Hsieh, CP; Sakai, K, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.14) | 18.7374 |
| 1990's | 5 (17.86) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 7 (25.00) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Okada, T | 1 |
| Shioda, K | 1 |
| Makiguchi, A | 1 |
| Suda, S | 1 |
| Mizutani, K | 1 |
| Sonoda, S | 1 |
| Wakita, H | 1 |
| Tucci, MC | 1 |
| Dvorkin-Gheva, A | 1 |
| Johnson, E | 1 |
| Wong, M | 1 |
| Szechtman, H | 1 |
| Wang, S | 1 |
| Zhang, QJ | 1 |
| Liu, J | 1 |
| Ali, U | 1 |
| Wu, ZH | 1 |
| Chen, L | 1 |
| Gui, ZH | 1 |
| Wang, Y | 1 |
| Hui, YP | 1 |
| Shin, EJ | 1 |
| Jeong, JH | 1 |
| Chung, YH | 1 |
| Kim, TW | 1 |
| Shin, CY | 1 |
| Kim, WK | 1 |
| Ko, KH | 1 |
| Kim, HC | 1 |
| Tarasiuk, A | 1 |
| Berdugo-Boura, N | 1 |
| Troib, A | 1 |
| Segev, Y | 1 |
| Yamada, N | 1 |
| Araki, H | 1 |
| Yoshimura, H | 1 |
| Wierońska, JM | 1 |
| Stachowicz, K | 2 |
| Brański, P | 1 |
| Pałucha-Poniewiera, A | 1 |
| Pilc, A | 2 |
| Trevisan da Rocha, J | 1 |
| Mozzaquatro Gai, B | 1 |
| Pinton, S | 1 |
| Bazanella Sampaio, T | 1 |
| Nogueira, CW | 1 |
| Zeni, G | 1 |
| Schrott, LM | 1 |
| Baumgart, MI | 1 |
| Zhang, X | 1 |
| Sparber, SB | 1 |
| Taylor, AJ | 1 |
| Bobik, A | 1 |
| Berndt, MC | 1 |
| Kannelakis, P | 1 |
| Jennings, G | 1 |
| Begg, DP | 1 |
| Hallam, KT | 1 |
| Norman, TR | 1 |
| Naghdi, N | 2 |
| Rezaei, M | 1 |
| Fathollahi, Y | 2 |
| Soleimannejad, E | 1 |
| Semnanian, S | 1 |
| Chojnacka-Wójcik, E | 1 |
| Kłak, K | 1 |
| Tzirogiannis, KN | 1 |
| Demonakou, MD | 1 |
| Papadimas, GK | 1 |
| Skaltsas, SD | 1 |
| Manta, GA | 1 |
| Kourentzi, KT | 1 |
| Alexandropoulou, KN | 1 |
| Hereti, RI | 1 |
| Mykoniatis, MG | 1 |
| Panoutsopoulos, GI | 1 |
| Ago, Y | 1 |
| Nakamura, S | 1 |
| Baba, A | 1 |
| Matsuda, T | 1 |
| Egawa, T | 1 |
| Ichimaru, Y | 1 |
| Imanishi, T | 1 |
| Sawa, A | 1 |
| Hsieh, CP | 1 |
| Sakai, K | 1 |
| Bruns, GC | 1 |
| Dage, RC | 1 |
| Janssen, PA | 2 |
| Grignaschi, G | 1 |
| Mantelli, B | 1 |
| Samanin, R | 1 |
| Meert, TF | 2 |
| Einat, H | 1 |
| Clenet, F | 1 |
| Shaldubina, A | 1 |
| Belmaker, RH | 1 |
| Bourin, M | 1 |
| Nisijima, K | 1 |
| Yoshino, T | 1 |
| Yui, K | 1 |
| Katoh, S | 1 |
| Colpaert, FC | 1 |
| Niemegeers, CJ | 1 |
| Gardner, CR | 1 |
3 reviews available for ritanserin and Disease Models, Animal
| Article | Year |
|---|---|
Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice.
Topics: Amphetamine-Related Disorders; Animals; Behavior, Animal; Brain; Bridged Bicyclo Compounds, Heterocy | 2008 |
Addiction and the potential for therapeutic drug development.
Topics: Alcoholism; Animals; Cocaine; Disease Models, Animal; Double-Blind Method; Humans; Research Design; | 1994 |
Ritanserin and alcohol abuse and dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Discrimination Learning; Disease Mo | 1994 |
1 trial available for ritanserin and Disease Models, Animal
| Article | Year |
|---|---|
Addiction and the potential for therapeutic drug development.
Topics: Alcoholism; Animals; Cocaine; Disease Models, Animal; Double-Blind Method; Humans; Research Design; | 1994 |
25 other studies available for ritanserin and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats.
Topics: Animals; Benzazepines; Cocaine; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibi | 2020 |
Ritanserin, a serotonin-2 receptor antagonist, inhibits functional recovery after cerebral infarction.
Topics: Animals; Cerebral Infarction; Disease Models, Animal; GAP-43 Protein; Gene Expression Regulation; Lo | 2018 |
5-HT2A/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).
Topics: Animals; Compulsive Behavior; Disease Models, Animal; Male; Obsessive-Compulsive Disorder; Piperazin | 2015 |
In vivo effects of activation and blockade of 5-HT(2A/2C) receptors in the firing activity of pyramidal neurons of medial prefrontal cortex in a rodent model of Parkinson's disease.
Topics: Action Potentials; Amphetamines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Decrease in the kainate-induced wet dog shake behavior in genetically epilepsy-prone rats: possible involvement of an impaired synaptic transmission to the 5-HT(2A) receptor.
Topics: Animals; Behavior, Animal; Cytoskeletal Proteins; Disease Models, Animal; Epilepsy; Kainic Acid; Ner | 2009 |
Role of growth hormone-releasing hormone in sleep and growth impairments induced by upper airway obstruction in rats.
Topics: Animals; Disease Models, Animal; Growth Disorders; Growth Hormone; Growth Hormone-Releasing Hormone; | 2011 |
Identification of antidepressant-like ingredients in ginseng root (Panax ginseng C.A. Meyer) using a menopausal depressive-like state in female mice: participation of 5-HT2A receptors.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug | 2011 |
On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice.
Topics: Amino Acids; Analysis of Variance; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, | 2012 |
Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system.
Topics: Animals; Antidepressive Agents; Benzene Derivatives; Cerebral Cortex; Depression; Disease Models, An | 2012 |
Prenatal opiate withdrawal activates the chick embryo hypothalamic pituitary-adrenal axis and dilates vitelline blood vessels via serotonin(2) receptors.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Chick Embryo; Corticosterone; Disease Models, Animal; Hypothal | 2002 |
Serotonin blockade protects against early microvascular constriction following atherosclerotic plaque rupture.
Topics: Animals; Arteriosclerosis; Blood Flow Velocity; Disease Models, Animal; Iliac Artery; Indans; Microc | 2004 |
Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Diazepam; Disease Models, Animal; Interpers | 2005 |
Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.
Topics: Amnesia; Animals; Behavior, Animal; Disease Models, Animal; Drug Interactions; Hippocampus; Male; Ma | 2006 |
Microinjection of ritanserin into the dorsal hippocampal CA1 and dentate gyrus decrease nociceptive behavior in adult male rat.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Hippocampus; Ma | 2006 |
Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Conflict, Psychological; Cyclopentanes; Dis | 2007 |
Effect of 5-HT(2) receptor blockade on cadmium-induced acute toxicity.
Topics: Animals; Apoptosis; Cadmium; Disease Models, Animal; In Situ Nick-End Labeling; Ketanserin; Liver Fa | 2007 |
Neither the 5-HT1A- nor the 5-HT2-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on forced-swimming-induced immobility in mice.
Topics: Analysis of Variance; Animals; Behavior, Animal; Desipramine; Disease Models, Animal; Drug Interacti | 1995 |
Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs.
Topics: Administration, Oral; Animals; Biological Availability; Blood Platelets; Blood Pressure; Coronary Th | 1994 |
The hypophagic effect of restraint stress in rats can be mediated by 5-HT2 receptors in the paraventricular nucleus of the hypothalamus.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amidines; Animals; Anorexia; Anorexia Nervosa; Disease Model | 1993 |
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors.
Topics: Animals; Antidepressive Agents; Benzylamines; Depression; Disease Models, Animal; Drug Interactions; | 2001 |
Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.
Topics: 5-Hydroxytryptophan; Animals; Anterior Hypothalamic Nucleus; Antidepressive Agents; Body Temperature | 2001 |
Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat.
Topics: 5-Hydroxytryptophan; Animals; Anti-Anxiety Agents; Anxiety; Chlordiazepoxide; Diazepam; Disease Mode | 1985 |
Recent developments in 5HT-related pharmacology of animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Buspirone; Disease Models, Animal; Piperidines; Pyrimidines; | 1986 |